China's economic and scientific and technological strength continues to improve rapidly, and China has been in the forefront of pharmaceutical innovation. With the introduction of medical health laws and policies, the continuous construction of drug R & D platforms, the rapid improvement of R & D capabilities and the efforts of domestic scholars, China's medical R & D has made great progress.
From August 18 to 19, the CPHI "thought sharing meeting" - 2022 new drug development and Cooperation Summit Forum was grandly opened in Suzhou Tantai Lake Hotel. With the theme of "creating new vitality and sharing new wisdom", this meeting will jointly explore the opportunities for China's source innovation, and accelerate the construction of an open communication platform for the innovation drug ecological chain. Nearly 70 top experts and scholars from the fields of small molecule innovative drugs, biological innovative drugs, new vaccines and mRNA vaccines were invited to participate in the conference, which attracted more than 1000 colleagues from domestic and foreign well-known pharmaceutical enterprises, biotechnology companies, academic and scientific research institutions, universities and industry associations.